7546-48-7

Basic information

• Product Name: 2-DIMETHYL (2-METHYL-1H-PYRROLO[2,3-B]PYRIDINE-3YL METHYL)-AMINE
• Synonyms: 2-DIMETHYL (2-METHYL-1H-PYRROLO[2,3-B]PYRIDINE-3YL METHYL)-AMINE;N,N-DiMethyl(2-Methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)MethanaMine
• CAS NO: 7546-48-7
• Molecular Formula: C11H15N3
• Molecular Weight: 189.2569
• Mol File: 7546-48-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-DIMETHYL (2-METHYL-1H-PYRROLO[2,3-B]PYRIDINE-3YL METHYL)-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-DIMETHYL (2-METHYL-1H-PYRROLO[2,3-B]PYRIDINE-3YL METHYL)-AMINE(7546-48-7)
• EPA Substance Registry System: 2-DIMETHYL (2-METHYL-1H-PYRROLO[2,3-B]PYRIDINE-3YL METHYL)-AMINE(7546-48-7)

Safety Data

• Hazardous Substances Data: 7546-48-7(Hazardous Substances Data)

Usage

General Description

2-DIMETHYL (2-METHYL-1H-PYRROLO[2,3-B]PYRIDINE-3YL METHYL)-AMINE is a chemical compound with the molecular formula C14H16N2. It is a derivative of the pyrrolopyridine family and contains a dimethylamino group. 2-DIMETHYL (2-METHYL-1H-PYRROLO[2,3-B]PYRIDINE-3YL METHYL)-AMINE has potential pharmaceutical applications, particularly in the field of medicinal chemistry and drug development. Its precise uses and properties are subject to further research and investigation, but it has the potential to contribute to the development of new treatments for various medical conditions.

Upstream product

• 23612-48-8 2-methyl-1H-pyrrolo[2,3-b]pyridine 
• 506-59-2 N,N-dimethylammonium chloride 
• 50-00-0 formaldehyd 
• 504-29-0 2-aminopyridine 
• 124-40-3 dimethyl amine 

Relevant articles and documents

PREPARATION OF 2-[2-METHYL-1-[[4-METHYLSULFONYL-2-(TRIFLUORO METHYL)PHENYL]METHYL] PYRROLO[2,3-B]PYRIDIN-3-YL]ACETIC ACID

The present invention relates to a novel compound of Formula IV and use of said compound for the preparation of 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl] methyl]pyrrolo[2,3-b]pyridine-3-yl]acetic acid [fevipiprant], Formula IV wherein A is SO2Me, halogen or a leaving group. The present invention further relates to a process of preparation of pharmaceutical acceptable salts of fevipiprant and composition thereof.

Fevipiprant selective prostaglandin DP2 (CRTh2) inhibitor treatment of asthma

Prostaglandin D2 (PGD2), a major prostanoid, releases from activated mast cells. It activates and recruits various inflammatory cells like eosinophils and basophils through DP2 receptors to the site of inflammation and further promotes late-phase allergic reactions. For the last decade, the scientific community has extensively explored this pathway and synthesized various specific DP2 receptor antagonists for the management of asthma. About 20 compounds with DP2 antagonistic activity have reached different stages of clinical development. Among these, fevipiprant is one of the most advanced oral DP2 inhibitors as it selectively blocks the DP2 receptors. Fevipiprant has demonstrated an acceptable safety profile in phase II studies as evident from significant reduction of moderate to severe asthma exacerbations. Currently this novel antiasthmatic drug is in phase III clinical trials. This review provides a brief overview of PGD2 blockers, particularly fevipiprant and its preclinical pharmacology and clinical development, by providing a summary of completed or ongoing clinical studies assessing its safety and efficacy in asthma.